Modern management of complex disease, like in oncology and cancer care, relies heavily on biomarker testing for diagnosis, selection of effective therapies, and treatment monitoring. As the number of actionable biomarkers continues to increase, serial single-gene testing has become less practical due to its large specimen requirements, long turnaround times, and cost- & labor-intensive bioinformatic data analysis. There is a rising need for more advanced technologies enabling multi-gene testing as a new standard of care. A multi-gene testing approach helps to ensure capturing all relevant biomarkers at once, making the most of limited sample tissue while also decreasing critical turnaround times.

Despite the overwhelming need for multi-gene and multi-biomarker testing, many clinicians and pathologists rely on outsourcing this service to specialized reference laboratories, leading to long turnaround times for results, and potentially suboptimal treatment decisions. The MODAPLEX platform automates multi-gene testing into a consolidated workflow with turn-around times of 4 hours. This allows hospitals, clinics, and molecular pathologies to bring this valuable technology in-house, facilitating faster results and better coordination of care.